

ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1 EVALUATION FORM 2A

For therapies that are not likely to be curative with primary endpoint of OS

Name of stu	dy:							
Study medicine:		Indication:	Indication:					
First author	:	Year:	Journal:					
Name of eva	aluator:							
If median O	S with the standard tre	eatment is ≤12 months						
GRADE 4	HR ≤0.65 <u>AND</u> gain ≥3	months						
	Increase in 2 year survi	ival ≥10%						
GRADE 3	HR ≤0.65 <u>AND</u> gain ≥2.	.0-<3 months						
GRADE 2	HR ≤0.65 <u>AND</u> gain ≥1.	.5-<2.0						
	HR >0.65-0.70 <u>AND</u> ga	in ≥1.5 months						
GRADE 1	HR >0.70 <u>OR</u> gain <1.5	months						
			Mark with √ if relevant					
	ry magnitude of clinic grade scored)	al benefit grade	4 3 2 1					

Non-curative setting grading - 5 and 4 indicates a substantial magnitude of clinical benefit



Quality of life/Grade 3-4 toxicities* assessment

Does s										
Are the	ere statistically significantly less grade 3-4 toxicities impactir	ng on daily	y well-beir	ng?*						
*This does not include alopecia, myelosuppression, but rather chronic nausea, diarrhoea, fatigue, etc.				Mark with √ if relevant						
Adjus	etments									
01.	Upgrade 1 level if improved QoL and/or less grade 3-4 toxicities impacting daily well-being are shown									
02.	02. If there is a long term plateau in the survival curve, and OS advantage continues to be observed at 5 years, <u>also score</u> according to form 1 (treatments with curative potential) and present both scores i.e. A/4.									
	al adjusted magnitude clinical benefit grade	5	4	3	2	1				

Non-curative setting grading - 5 and 4 indicates a substantial magnitude of clinical benefit

OS, overall survival; QoL, quality of Life